297 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Recruiting Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
Conditions: Sarcoma;   Desmoplastic Small Round Cell Tumor (DSRCT)
Intervention: Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
2 Withdrawn A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)
Condition: Non Muscle Invasive Bladder Cancer
Intervention: Device: TC-3 hydrogel
3 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
4 Not yet recruiting Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Conditions: B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent B Lymphoblastic Lymphoma;   Recurrent T Lymphoblastic Leukemia/Lymphoma;   Refractory B Lymphoblastic Lymphoma;   Refractory T Lymphoblastic Lymphoma;   T Acute Lymphoblastic Leukemia;   T Lymphoblastic Lymphoma
Interventions: Drug: Asparaginase;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
5 Not yet recruiting CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
Conditions: Peripheral T-Cell Lymphoma;   Angioimmunoblastic T Cell Lymphoma;   ALK-negative Anaplastic Large Cell Lymphoma;   Enteropathy Associated T Cell Lymphoma;   Subcutaneous Panniculitis Like T Cell Lymphoma;   Acute Adult T-Cell Leukemia/Lymphoma
Interventions: Drug: CEOP/IVE/GDP chemotherapy regimen;   Drug: CEOP chemotherapy regimen for 8 cycles
6 Completed A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Rituximab
7 Recruiting The Research of Standard Diagnosis and Treatment for HSPN in Children
Condition: Henoch-Schoenlein Purpura Nephritis
Interventions: Drug: Prednisone;   Drug: Cyclophosphamide(CTX);   Drug: Mycophenolate mofetil(MMF);   Drug: Leflunomide(LEF);   Drug: Angiotensin-converting enzyme inhibitor(ACEI);   Drug: Methylprednisolone
8 Recruiting High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
Condition: Diffuse Large B-cell-lymphoma
Interventions: Drug: Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);   Drug: Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
9 Recruiting Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: Metformin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: pegfilgrastim
10 Not yet recruiting Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Fludarabine monophosphate;   Drug: Bendamustine;   Biological: Activated T-Cell Infusion;   Drug: Lenalidomide;   Behavioral: Phone Calls
11 Not yet recruiting Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Condition: Adult Glioblastoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Radiation: Radiation Therapy;   Drug: Temozolomide
12 Not yet recruiting A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
13 Not yet recruiting Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Procedure: Autologous bone marrow transplantation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Alemtuzumab
14 Not yet recruiting CD19+ CAR T Cells for Lymphoid Malignancies
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Procedure: T Cell Infusion
15 Not yet recruiting Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
Conditions: Acute Myeloid Leukemia in Remission;   Primary Myelofibrosis;   Primary Myelofibrosis, Prefibrotic Stage;   Secondary Acute Myeloid Leukemia;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
16 Completed Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Conditions: Neutropenia;   Breast Cancer
Interventions: Biological: F-627;   Drug: EC regimen
17 Not yet recruiting Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
Conditions: Anus Neoplasms;   Carcinoma, Squamous Cell;   Anus Diseases;   Neoplasms;   Neoplasms, Squamous Cell;   Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Capecitabine;   Drug: Mitomycins;   Radiation: Radiotherapy
18 Recruiting A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Condition: Neutropenia
Interventions: Biological: F-627;   Drug: TAC regimen
19 Recruiting A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
Condition: Neutropenia
Interventions: Biological: F-627;   Biological: Filgrastim;   Drug: Epirubicin and Cyclophosphamide
20 Recruiting Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients
Condition: Glioblastoma
Interventions: Drug: supra-early TEMODAL® chemotherapy;   Drug: standard TEMODAL® chemotherapy;   Radiation: Radiotherapy 60Gy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years